News
Over 30 Scottish landmarks, including Edinburgh Castle, showed their support by lighting up in the colours of Parkinson's UK
It's our mission to improve life for everybody affected by Parkinson's. To stay true to this, we must proactively tackle barriers to accessing our support and NHS services, and barriers to participating in medical research.
Genna, 39, has Parkinson's. She's designed an exclusive range of T-shirts and bags for Next.
This new partnership will help more people understand Parkinson's and raise vital funds to support others with the condition.
The latest report by the Royal College of Speech and Language Therapists shows the impact of lockdown on this vital therapy.
Research shows it's possible to identify Parkinson's based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
We're investing up to £1.2m into pioneering research in partnership with the University of Sheffield, which aims to develop a drug to protect dopamine-producing brain cells.
The earlier groundbreaking clinical trial proved inconclusive. So we're launching a new company tasked with planning a possible new trial.
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson's.
Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
We've partnered with Alzheimer's Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we've developed a new resource to help lab-based researchers with patient and public involvement (PPI).